Saturday, July 11, 2026
🇺🇸 FDA

Drug profile · INN

low-dose

low-dose is an FDA-listed pharmaceutical active ingredient.

NMPA: clinical trials
Patents linked 14
Pipeline programs 74
News articles 0
Drug details — low-dose
Class
—
Route
—
Patents
14
Programs
74
Data quality
0.70
← All drugs Related patents Pipeline programs Drug news hub Event calendar

Quick answer

low-dose is an FDA-listed pharmaceutical active ingredient.

Key facts

INN low-dose

Approval history

Authority Status Date
NMPA clinical trials —

Pipeline programs

Browse pipeline
  1. 2021/3336 Phase 3 · George Institute for · Maintenance treatment in metastatic non-squamous lung cancer
  2. ALKS 9072, Low Dose Phase 3 · Alkermes Pharma Ireland · Schizophrenia
  3. Betamethasone Microsphere (DE-102） Low Dose Phase 3 · Santen Oy · Diabetic Macular Edema
  4. CX842A2303 Phase 3 · Anaxis Pharma · Erosive esophagitis (EE) due to gastroesophageal reflux dise
  5. Combined use of TPO-RAs with low-dose anti-CD20 antibody Phase 3 · Chinese Academy of · Immune Thrombocytopenia (ITP)
  6. EFC14771 Phase 3 · Sanofi-Aventis U.S · Respiratory tract diseases - Wheezing, Asthma
  7. EryDex Low dose DSP Phase 3 · Quince Therapeutics · Nervous System Disease
  8. Low-dose complex B-vitamins Phase 3 · Chinese Academy of · Hyperhomocysteinemia

Related patents

Browse patents

  1. US 12410249

    Low dose antibody-based methods for treating hematologic malignancies

    Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12208093

    Use of low dose emetine for inhibition of human cytomegalovirus (HCMV)

    Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. AU 2022263543

    Pharmaceutical compositions comprising sorbitan esters

    Expires Wed May 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11292835

    Low dose antibody-based methods for treating hematologic malignancies

    Expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11253511

    Use of low dose emetine for inhibition of human cytomegalovirus (HCMV)

    Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. CA 3172871

    COMPOSITIONS DE POLYPEPTIDES DE FUSION D'IL-2 ET LEURS PROCEDES DE FABRICATION ET D'UTILISATION

    Expires Wed Nov 13 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. CA 3172874

    COMPOSITIONS DE POLYPEPTIDES DE FUSION D'IL-2 ET LEURS PROCEDES DE FABRICATION ET D'UTILISATION

    Expires Wed Nov 13 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10849911

    Low dose compositions of Aramachol salts

    Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10842814

    Use of low dose arsenic for preserving genomic integrity

    Expires Mon Nov 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10722478

    Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine

    Expires Mon Jul 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. EP 3182958

    ARIPIPRAZOL-PRODRUGZUSAMMENSETZUNG

    Expires Tue Jun 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 9474728

    Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine

    Expires Mon Oct 20 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 2016228376

    MONOMETHYLFUMARATE PRODRUG COMPOSITIONS

    Expires Wed Aug 06 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 8288342

    Methods for treating vasomotor symptoms in castrated prostatic cancer patients with low dose cyproterone acetate

    Expires Mon Oct 11 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is low-dose?

low-dose is an FDA-listed pharmaceutical active ingredient.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.